G

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Senior Scientist - AI-Enabled De Novo Antibody Discovery, Protein Therapeutics

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeFoster City, CA, USA

About the Job

Requirements

  • A Bachelor's degree and at least 8 years of relevant experience, a Master's degree and at least 6 years of relevant experience, or a PhD or PharmD and at least 2 years of relevant experience.
  • Industry experience in antibody discovery or engineering spanning target assessment through lead optimization.
  • Ability to independently design, lead, and execute antibody discovery campaigns in a cross-functional environment.
  • Experience with conventional antibodies and VHHs.
  • Expertise in structural biology and protein structure-function relationships, including evaluating experimental and predicted antibody-target structures.
  • Experience connecting epitope selection, target biology, and therapeutic mechanism of action to antibody discovery strategies.
  • Experience with antibody library design and screening technologies, including display-based or high-throughput recombinant screening.
  • Hands-on experience with one or more antibody library design or screening approaches.
  • Familiarity with the applications and limitations of artificial intelligence and machine learning approaches for biologics discovery and optimization.
  • Familiarity with protein language models, inverse folding, structure prediction or co-folding, diffusion or flow models, and iterative data-driven lead optimization.
  • Experience applying artificial intelligence or machine learning approaches to antibody discovery or optimization challenges.
  • Working proficiency with Python, artificial intelligence-assisted coding tools, and Linux command-line or high-performance computing environments for scientific analysis, workflow development, and rapid prototyping.
  • Scientific judgment and ability to integrate computational and experimental evidence.
  • Ability to collaborate with machine learning scientists and protein production and screening teams.

Responsibilities

  • Lead de novo antibody discovery and optimization campaigns from target and epitope assessment through design, screening, iteration, and hit selection.
  • Develop integrated computational and experimental screening strategies for de novo designs, including candidate prioritization, library design, multiplexing, and recombinant and display-based approaches.
  • Evaluate experimental and predicted structural models to prioritize biologically relevant epitopes and guide discovery strategies.
  • Integrate computational, structural, binding, functional, and developability data to inform campaign iteration and binder advancement decisions.
  • Rapidly prototype computational workflows that address antibody discovery and optimization needs.
  • Collaborate with machine learning scientists to refine, scale, and implement broadly useful computational solutions.
  • Partner with data scientists, structural biologists, and high-throughput screening scientists to build scalable lab-in-the-loop capabilities for de novo antibody discovery and optimization.
  • Bridge computational and experimental antibody discovery teams supporting project teams across Gilead therapeutic areas.

Desired Qualifications

  • A PhD in structural biology, protein engineering, biochemistry, biophysics, computational protein design, or a related discipline.

About the Company

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Gilead Sciences is a biopharmaceutical company that discovers, develops and sells medicines for HIV, viral hepatitis and other liver diseases, cancer and inflammatory conditions. Its HIV business covers both treatment, led by the once-daily pill Biktarvy, and prevention, including Descovy and Yeztugo, a lenacapavir injection given twice a year. In cancer, its Kite unit makes CAR T-cell therapies from patients' own immune cells, and Trodelvy is an antibody-drug conjugate for breast cancer. Gilead earns revenue by selling its drugs to wholesalers, specialty pharmacies, hospitals and governments worldwide after regulatory approval. The company was founded in 1987 and is headquartered in Foster City, California.

Company size
10,001+
Company stage
IPO
Headquarters
Foster City, CA
Founded
1987

Recently Posted Jobs

Explore more opportunities at Gilead Sciences

See more jobs